

Sri Lanka Support for Human Papillomavirus Vaccine (HPV)

This Decision Letter sets out the Programme Terms of a Programme.

1.	Country: Sri Lanka							
2.	Vaccines grant number: 17-LKA-19b-X Cash support grant number: 17-LKA-08f-Y							
3.	Date of Decision Letter: 3 April 2017							
4.	Date of the partnership framework agreement: 3 April 2014							
5.	Programme title: New Vaccine Support (NVS), HPV Routine							
6.	Vaccine type: HPV							
7.	Requested product presentation and formulation of vaccine: <i>HPV Quadrivalent, 1 dose(s) per vial, LIQUID</i>							
8.	<i>Programme duration</i> ¹ : 2017							
9.	Programme Budget (indicative): (subject to the terms of the Partnership Framework Agreement)							
	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 30%;"></th> <th style="width: 35%; text-align: center;">2017</th> <th style="width: 35%; text-align: center;">Total²</th> </tr> </thead> <tbody> <tr> <td>Programme Budget (US\$)</td> <td style="text-align: center;">US\$1,055,500</td> <td style="text-align: center;">US\$1,055,500</td> </tr> </tbody> </table>			2017	Total ²	Programme Budget (US\$)	US\$1,055,500	US\$1,055,500
	2017	Total ²						
Programme Budget (US\$)	US\$1,055,500	US\$1,055,500						
10.	Vaccine introduction grant: US\$ 420,000 to be used within 12 months of disbursement.							
11.	Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ³							
	<table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 70%;">Type of supplies to be purchased with Gavi funds in each year</th> <th style="width: 30%; text-align: center;">2017</th> </tr> </thead> <tbody> <tr> <td>Number of HPV vaccines doses</td> <td style="text-align: center;">229,700</td> </tr> <tr> <td>Annual Amounts (US\$)</td> <td style="text-align: center;">US\$1,055,500</td> </tr> </tbody> </table>		Type of supplies to be purchased with Gavi funds in each year	2017	Number of HPV vaccines doses	229,700	Annual Amounts (US\$)	US\$1,055,500
Type of supplies to be purchased with Gavi funds in each year	2017							
Number of HPV vaccines doses	229,700							
Annual Amounts (US\$)	US\$1,055,500							
12.	Procurement agency: UNICEF. The Country shall release its co-financing payments each year to UNICEF.							
13.	Self-procurement: Not applicable							

¹ This is the entire duration of the Programme.

² This is the total amount endorsed by Gavi for the entire duration of the Programme.

³ This is the amount that Gavi has approved.

- 14. Co-financing obligations:** Reference code: 17-LKA-19b-X-C
According to the co-financing policy, the Country falls within the group Fully self-financing.
The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2017
Number of vaccines doses	229,700
Number of AD syringes	243,100
Number of Safety boxes	2,675
Value of vaccine doses (US\$)	1,033,594
Total co-financing payments (US\$) (including freight)	US\$1,068,000

- 15. Operational support for campaigns:** Not applicable

16. Additional reporting requirements:

Reports other information	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	May
In accordance with applicable Gavi processes, Country shall report on programmatic performance.	As per agreed schedule for each indicator in the Grant Performance Framework
In accordance with applicable Gavi processes, Country shall report on financial performance through periodic financial report on all cash support.	Periodic 6 monthly financial report with variance analysis due 45 days after period end. Detailed budget activity reporting Asset listings
In accordance with applicable Gavi processes, Country shall report on financial performance through annual financial reports on all cash support.	Annual financial report with variance analysis due 3 months following end of Country's fiscal year.
External Audit Report	6 months after end of grant (18 months after Gavi disbursement of VIG funds)
In accordance with applicable Gavi guidelines, Country shall report on general programme information, including Immunisation Financing and Expenditure, and Data Quality Reports	As per Guidelines on Reporting and Renewal

- 17. Financial clarifications:** Not applicable

- 18. Other conditions:** Not applicable

On behalf of Gavi

Signed by,

Hind Khatib-Othman
Managing Director, Country Programmes
3 April 2017